Cefuroxime Capsules

This product is a first-generation cephalosporin, which has good antibacterial effect on some strains of Gram-positive cocci such as non-penicillinase-producing and penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, group A hemolytic Streptococcus, Streptococcus pneumoniae and viridans Streptococcus. Anaerobic Gram-positive bacteria are mostly sensitive to this product, while Bacteroides fragilis is resistant to it. Methicillin-resistant Staphylococci and Enterococci are resistant to this product. The effect of this product on Gram-positive and Gram-negative bacteria is similar to that of cephalexin. This product has a certain effect on Neisseria gonorrhoeae, and is also active against enzyme-producing Neisseria gonorrhoeae; its activity against Haemophilus influenzae is poor.

The main ingredient of this product is cefradine. Its chemical name is: (6R, 7R)-7[(R)-2-amino-2-(1,4-cyclohexenyl)acetylamino]-3-methyl-8-oxo-5-thia-1-aminobicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

The content of this product is white to off-white or light yellow powder.

It is suitable for acute pharyngitis, tonsillitis, otitis media, bronchitis, pneumonia and other respiratory tract infections, urogenital tract infections and skin and soft tissue infections caused by sensitive bacteria. This product is an oral preparation and should not be used for severe infections.

Adult dose: Oral, generally 0.25-0.5g once, once every 6 hours, with a maximum daily dose of 4g. Child dose: 6.25-12.5mg/kg once according to body weight, once every 6 hours. Elderly patients: Elderly patients with impaired renal function should appropriately reduce the dose or extend the dosing interval.

The adverse reactions of this product are relatively mild and the incidence is also low, about 6%. Gastrointestinal reactions such as nausea, vomiting, diarrhea, and upper abdominal discomfort are relatively common. Pseudomembranous colitis (therefore, for patients who develop diarrhea while receiving antibacterial treatment, it should be considered whether they have pseudomembranous colitis. This is very important. For patients with mild symptoms of enteritis, the symptoms may be relieved after stopping the drug. For moderate or severe patients, measures should be taken according to the patient's symptoms), eosinophilia. Direct Coombs test positive reaction. Peripheral blood leukocytes and neutrophils decrease in some patients. A small number of patients may have a temporary increase in blood urea ammonia, serum aminotransferase, serum alkaline phosphatase, bilirubin, and lactate dehydrogenase.

This product is contraindicated for patients who are allergic to cephalosporins or have a history of anaphylactic shock or immediate reaction to penicillin.

Precautions for children: Adverse reactions reported after domestic marketing may cause hematuria when using this product. Children are susceptible to the disease. Children should be cautious when using this product and use it under detection. Precautions for pregnancy and lactation: This product can enter the fetal blood circulation through the placental barrier and can also enter breast milk. Pregnant and lactating women should use it with caution. Precautions for the elderly: Not yet clear.

1. Cephalosporins can delay the excretion of phenytoin sodium in the renal tubules. 2. Phenylbutazone combined with cephalosporin antibiotics can increase renal toxicity. 3. Combined with strong diuretics can increase renal toxicity. 4. Combined with mecillinam, it has a synergistic effect on Gram-negative rods such as Escherichia coli and Salmonella. 5. Probenecid can delay the excretion of this product.

Drug cool storage area (below 20℃)

0.25 g

24 months.

Shandong Zibo Xinda Pharmaceutical Co., Ltd.

• Founded in:

  1993-03-11

• Address:

  No. 1, Lutai Avenue, Zibo High-tech Zone

• Tax NO.:

  9137030361328152XT

• Registered Funds:

  84.93 million yuan

• Website:

  Log in to view

• Email:

  Log in to view